Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,311 shares of the medical research company’s stock after acquiring an additional 152 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Charles River Laboratories International were worth $854,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Charles River Laboratories International by 61.4% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,421 shares of the medical research company’s stock valued at $702,000 after acquiring an additional 921 shares during the last quarter. Alliancebernstein L.P. increased its stake in Charles River Laboratories International by 1.0% during the first quarter. Alliancebernstein L.P. now owns 83,744 shares of the medical research company’s stock worth $24,272,000 after purchasing an additional 816 shares during the period. Arizona State Retirement System increased its stake in shares of Charles River Laboratories International by 0.5% during the first quarter. Arizona State Retirement System now owns 14,480 shares of the medical research company’s stock worth $4,197,000 after buying an additional 73 shares during the period. Swiss National Bank increased its stake in shares of Charles River Laboratories International by 1.2% during the first quarter. Swiss National Bank now owns 113,700 shares of the medical research company’s stock worth $32,954,000 after buying an additional 1,400 shares during the period. Finally, Sowell Financial Services LLC increased its stake in shares of Charles River Laboratories International by 1.4% during the first quarter. Sowell Financial Services LLC now owns 4,045 shares of the medical research company’s stock worth $1,363,000 after buying an additional 57 shares during the period. 93.28% of the stock is currently owned by institutional investors.

Shares of NYSE CRL opened at $439.95 on Wednesday. The company has a market capitalization of $22.17 billion, a P/E ratio of 56.69, a price-to-earnings-growth ratio of 3.07 and a beta of 1.14. The business’s 50-day moving average price is $418.90 and its two-hundred day moving average price is $360.20. Charles River Laboratories International, Inc. has a one year low of $205.97 and a one year high of $450.84. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.36 and a quick ratio of 1.15.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Tuesday, August 3rd. The medical research company reported $2.61 EPS for the quarter, beating the consensus estimate of $2.38 by $0.23. Charles River Laboratories International had a return on equity of 23.59% and a net margin of 12.10%. The firm had revenue of $914.61 million during the quarter, compared to analysts’ expectations of $880.72 million. During the same quarter in the prior year, the firm posted $1.58 EPS. The company’s revenue for the quarter was up 34.0% on a year-over-year basis. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.25 EPS for the current year.

In related news, VP William D. Barbo sold 12,387 shares of the firm’s stock in a transaction on Friday, August 6th. The stock was sold at an average price of $402.82, for a total transaction of $4,989,731.34. Following the sale, the vice president now owns 4,371 shares of the company’s stock, valued at approximately $1,760,726.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director George Massaro sold 2,539 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 31st. The shares were sold at an average price of $442.48, for a total value of $1,123,456.72. Following the completion of the sale, the director now directly owns 4,855 shares in the company, valued at approximately $2,148,240.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,900 shares of company stock worth $16,673,320. 1.20% of the stock is owned by corporate insiders.

Several equities research analysts have recently weighed in on CRL shares. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating and set a $458.00 price objective for the company. in a report on Wednesday, September 15th. Credit Suisse Group increased their price objective on Charles River Laboratories International from $385.00 to $420.00 and gave the stock a “neutral” rating in a research report on Thursday, August 5th. Argus raised their price target on Charles River Laboratories International from $390.00 to $480.00 and gave the company a “buy” rating in a research report on Monday, August 23rd. UBS Group increased their price objective on Charles River Laboratories International from $390.00 to $465.00 and gave the company a “buy” rating in a research note on Tuesday, August 17th. Finally, Robert W. Baird raised their price target on Charles River Laboratories International from $410.00 to $461.00 and gave the stock an “outperform” rating in a research note on Thursday, August 5th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $400.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

Featured Story: The components of the Stochastic Momentum Index

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.